What is a Brixadi injection?: Understanding the OUD Treatment
•
3 min read
The U.S. Food and Drug Administration (FDA) approved Brixadi (buprenorphine) extended-release injection in May 2023 for the treatment of moderate to severe opioid use disorder (OUD). This medication provides a new option for patients, delivering a steady dose of medicine to help manage withdrawal symptoms and cravings.